The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.
M. S. Gordon
Research Funding - Exelixis
N. J. Vogelzang
Research Funding - Exelixis
P. Schoffski
Research Funding - Exelixis
A. Daud
Research Funding - Exelixis
A. I. Spira
No relevant relationships to disclose
B. A. O'Keeffe
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
T. Rafferty
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Y. Lee
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
R. Berger
Research Funding - Exelixis
G. Shapiro
Research Funding - Exelixis